Mainz Biomed B.V. (MYNZ)

Market Cap	22.39M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	20.36M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,916
Open	1.10
Previous Close	1.10
Day's Range	1.04 - 1.11
52-Week Range	1.03 - 9.03
Beta	0.69
Analysts	Strong Buy
Price Target	8.00 (+640.74%)
Earnings Date	Nov 16, 2023

About MYNZ

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 5, 2021
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: MYNZ

Financial Performance

In 2022, MYNZ's revenue was $529,877, a decrease of -8.22% compared to the previous year's $577,348. Losses were -$26.39 million, 125.7% more than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for MYNZ stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 640.74% from the latest price.

Price Target

$8.0

(640.74% upside)

Analyst Consensus: Strong Buy